JPS6051189B2
(ja)
*
|
1980-07-21 |
1985-11-12 |
株式会社日立製作所 |
磁気バブル駆動回路
|
JPS60226873A
(ja)
*
|
1984-03-28 |
1985-11-12 |
Sankyo Co Ltd |
1,3−ベンゾオキサチオ−ル誘導体及びその製法
|
CN1003445B
(zh)
*
|
1984-10-03 |
1989-03-01 |
武田药品工业株式会社 |
噻唑烷二酮衍生物,其制备方法和用途
|
JPH0653738B2
(ja)
*
|
1985-02-26 |
1994-07-20 |
三共株式会社 |
チアゾリジン誘導体
|
DK173350B1
(da)
|
1985-02-26 |
2000-08-07 |
Sankyo Co |
Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
|
US4703052A
(en)
*
|
1985-05-21 |
1987-10-27 |
Pfizer Inc. |
Hypoglycemic thiazolidinediones
|
US4738972A
(en)
*
|
1985-05-21 |
1988-04-19 |
Pfizer Inc. |
Hypoglycemic thiazolidinediones
|
JPH06779B2
(ja)
*
|
1985-06-10 |
1994-01-05 |
武田薬品工業株式会社 |
チアゾリジオン誘導体およびそれを含んでなる医薬組成物
|
JPS62234085A
(ja)
*
|
1985-12-18 |
1987-10-14 |
Sankyo Co Ltd |
チアゾリジン誘導体を有効成分とする糖尿病性合併症治療剤
|
US4873255A
(en)
*
|
1987-02-04 |
1989-10-10 |
Sankyo Company Limited |
Thiazolidinone derivatives, their preparation and their use
|
JP2574845B2
(ja)
*
|
1987-02-04 |
1997-01-22 |
三共株式会社 |
チアゾリジン化合物
|
US4791125A
(en)
*
|
1987-12-02 |
1988-12-13 |
Pfizer Inc. |
Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
|
US4798835A
(en)
*
|
1987-12-02 |
1989-01-17 |
Pfizer Inc. |
dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
|
US5260294A
(en)
*
|
1988-08-09 |
1993-11-09 |
Hoffman-La Roche Inc. |
Chromanes and their pharmaceutical compositions and methods
|
US5132310A
(en)
*
|
1988-08-09 |
1992-07-21 |
Hoffmann-La Roche Inc. |
Pharmacologically active chromanes
|
US5015661A
(en)
*
|
1988-08-09 |
1991-05-14 |
Hoffmann-La Roche Inc. |
Chromanes and their pharmaceutical compositions and methods
|
GB8919417D0
(en)
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
US5053420A
(en)
*
|
1989-10-13 |
1991-10-01 |
Pershadsingh Harrihar A |
Thiazolidine derivatives for the treatment of hypertension
|
JP2826379B2
(ja)
*
|
1990-01-22 |
1998-11-18 |
三共株式会社 |
チアゾリジン誘導体を有効成分とする肥満性高血圧症治療剤
|
US5143930A
(en)
*
|
1990-02-07 |
1992-09-01 |
Sankyo Company, Limited |
Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
|
US5356913A
(en)
*
|
1990-02-09 |
1994-10-18 |
The Upjohn Company |
Use of insulin sensitizing agents to treat hypertension
|
ATE93138T1
(de)
*
|
1990-02-09 |
1993-09-15 |
Upjohn Co |
Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
|
ATE205206T1
(de)
*
|
1990-04-27 |
2001-09-15 |
Sankyo Co |
Benzylidenthiazolidinderivate, ihre herstellung und ihre anwendung als lipidperoxid-inhibitoren
|
GB9023584D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
CA2082003A1
(en)
*
|
1991-11-20 |
1993-05-21 |
David Laffan |
Process for the preparation of substituted pentaalkylchromenes
|
ATE157864T1
(de)
*
|
1991-12-18 |
1997-09-15 |
Warner Lambert Co |
Verfahren für die herstellung einer festen dispersion
|
NO302519B1
(no)
*
|
1991-12-26 |
1998-03-16 |
Sankyo Co |
Tiazolidinforbindelser som inneholder en kinongruppe, og farmasöytisk preparat
|
NO302471B1
(no)
*
|
1991-12-26 |
1998-03-09 |
Sankyo Co |
Tiazolidinforbindelser og farmasöytisk preparat
|
CA2089013A1
(en)
*
|
1992-02-21 |
1993-08-22 |
Josef Heveling |
Process for the preparation of 6-hydroxy-2, 5, 7, 8- tetraalkyl-2-(4-aminophenoxymethyl) chromans
|
CA2089012A1
(en)
*
|
1992-02-21 |
1993-08-22 |
Josef Heveling |
Process for the preparation of 6-hydroxy-2,5,7,8-tetra- alkyl-2-(4-aminophenoxymethyl) chromans
|
ES2139633T3
(es)
|
1992-08-31 |
2000-02-16 |
Sankyo Co |
Derivados de oxazolidina con propiedades anti-diabetica y anti-obesidad, su preparacion y su utilizacion terapeutica.
|
JPH0631079U
(ja)
*
|
1992-09-22 |
1994-04-22 |
沖電線株式会社 |
シート付き小型smtコネクタ
|
US5594016A
(en)
*
|
1992-12-28 |
1997-01-14 |
Mitsubishi Chemical Corporation |
Naphthalene derivatives
|
WO1994019347A1
(en)
*
|
1993-02-24 |
1994-09-01 |
Sankyo Company, Limited |
Arteriosclerosis remedy
|
USRE39384E1
(en)
|
1993-09-01 |
2006-11-07 |
Smithkline Beecham P.L.C. |
Substituted thiazolidinedione derivatives
|
CN1103590C
(zh)
*
|
1993-09-15 |
2003-03-26 |
三共株式会社 |
使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作
|
US6046222A
(en)
*
|
1993-09-15 |
2000-04-04 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
AU749416B2
(en)
*
|
1993-09-15 |
2002-06-27 |
Daiichi Sankyo Company, Limited |
Use of thiazolidinediones to prevent or delay onset of NIDDM
|
US5478852C1
(en)
*
|
1993-09-15 |
2001-03-13 |
Sankyo Co |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
|
US5874454A
(en)
*
|
1993-09-15 |
1999-02-23 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
WO1995018125A1
(fr)
*
|
1993-12-27 |
1995-07-06 |
Japan Tobacco Inc. |
Derive d'isoxazolidinedione et son utilisation
|
CZ289317B6
(cs)
*
|
1994-04-11 |
2002-01-16 |
Sankyo Company Limited |
Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
|
US5594015A
(en)
*
|
1994-06-22 |
1997-01-14 |
Regents Of The University Of California |
Thiazolidine derivatives for the treatment of psoriasis
|
CA2159938A1
(en)
*
|
1994-10-07 |
1996-04-08 |
Hiroaki Yanagisawa |
Oxime derivatives, their preparation and their therapeutic use
|
US5708012A
(en)
*
|
1995-04-28 |
1998-01-13 |
Sankyo Company, Limited |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
|
IL118474A
(en)
*
|
1995-06-01 |
2001-08-08 |
Sankyo Co |
Benzimideol derivatives and pharmaceutical preparations containing them
|
TW474809B
(en)
*
|
1995-07-03 |
2002-02-01 |
Sankyo Co |
A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
|
CN1192683A
(zh)
*
|
1995-08-10 |
1998-09-09 |
沃尼尔·朗伯公司 |
减少非胰岛素依赖型糖尿病患者外源性胰岛素给药量的方法
|
WO1997018811A1
(en)
*
|
1995-11-17 |
1997-05-29 |
Warner-Lambert Company |
A method of treating myotonic dystrophy
|
EP0783888A1
(en)
*
|
1995-12-26 |
1997-07-16 |
Sankyo Company Limited |
Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
|
IN182496B
(da)
*
|
1996-02-20 |
1999-04-17 |
Reddy Research Foundation |
|
IL120443A
(en)
*
|
1996-03-18 |
2000-07-16 |
Sankyo Co |
Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
|
EP0916651B1
(en)
*
|
1996-04-04 |
2003-10-15 |
Sankyo Company, Limited |
Phenylalkylcarboxylic acid derivatives
|
DE69625795T2
(de)
*
|
1996-04-09 |
2003-08-14 |
Reddys Lab Ltd Dr |
Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven Eigenschaften, Verfahren zu deren Herstellung und pharmazeutischen Zusammenstellungen, die sie enthalten
|
US5919782A
(en)
*
|
1996-05-06 |
1999-07-06 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US5889025A
(en)
*
|
1996-05-06 |
1999-03-30 |
Reddy's Research Foundation |
Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US5801173A
(en)
*
|
1996-05-06 |
1998-09-01 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
ZA973848B
(en)
*
|
1996-05-06 |
1997-12-02 |
Reddy Research Foundation |
Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
|
WO1997043283A1
(de)
*
|
1996-05-16 |
1997-11-20 |
Boehringer Mannheim Gmbh |
Neues verfahren zur herstellung von troglitazone
|
DE19619819A1
(de)
*
|
1996-05-16 |
1997-11-20 |
Boehringer Mannheim Gmbh |
Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltenden Arzneimittel
|
CA2257284C
(en)
*
|
1996-05-31 |
2005-10-04 |
Sankyo Company Limited |
Remedy for autoimmune diseases
|
GB9611947D0
(en)
*
|
1996-06-07 |
1996-08-07 |
Glaxo Group Ltd |
Medicaments
|
JP2000511875A
(ja)
*
|
1996-06-19 |
2000-09-12 |
ドクター・レディーズ・リサーチ・ファウンデーション |
抗糖尿病活性を増強されたトログリタゾンの新規な多形型及びそれらの製造方法
|
US6372750B2
(en)
|
1996-07-01 |
2002-04-16 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
|
US5885997A
(en)
*
|
1996-07-01 |
1999-03-23 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
USRE39266E1
(en)
*
|
1996-07-01 |
2006-09-05 |
Dr. Reddy's Laboratories, Limited |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
CZ298812B6
(cs)
|
1996-07-01 |
2008-02-13 |
Dr. Reddy's Laboratories Limited |
Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí
|
US6114526A
(en)
*
|
1996-07-01 |
2000-09-05 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
BR9710272A
(pt)
*
|
1996-07-12 |
1999-08-10 |
Smithkline Beecham Plc |
Novo tratamento de resisténcia a leptina
|
EP0958818A1
(en)
*
|
1996-09-12 |
1999-11-24 |
Sankyo Company Limited |
Glutathione reductase activity potentiator containing troglitazone
|
EP0974348B1
(en)
*
|
1996-11-08 |
2008-07-02 |
Nippon Chemiphar Co., Ltd. |
Visceral fat lowering agent
|
JP2001514663A
(ja)
*
|
1997-03-12 |
2001-09-11 |
エスモンド,ロバート ダブリュー. |
アルツハイマー病を処置または予防するための方法
|
US6011036A
(en)
*
|
1997-04-15 |
2000-01-04 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
|
US6011031A
(en)
*
|
1997-05-30 |
2000-01-04 |
Dr. Reddy's Research Foundation |
Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
|
SE9702305D0
(sv)
*
|
1997-06-17 |
1997-06-17 |
Astra Ab |
New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
|
EA003144B1
(ru)
*
|
1997-06-18 |
2003-02-27 |
Смитклайн Бичам Плс |
Способ лечения диабета тиазолидиндионом и метформином
|
UA67743C2
(uk)
|
1997-06-18 |
2004-07-15 |
Смітклайн Бічам П.Л.С. |
Фармацевтична композиція, що містить тіазолідиндіон і сульфонілсечовину, для лікування діабету
|
GB9715306D0
(en)
*
|
1997-07-18 |
1997-09-24 |
Smithkline Beecham Plc |
Novel method of treatment
|
GB9715295D0
(en)
*
|
1997-07-18 |
1997-09-24 |
Smithkline Beecham Plc |
Novel method of treatment
|
US6171856B1
(en)
|
1997-07-30 |
2001-01-09 |
Board Of Regents, The University Of Texas System |
Methods and compositions relating to no-mediated cytotoxicity
|
FR2766820B1
(fr)
*
|
1997-07-31 |
1999-10-22 |
Rhodia Chimie Sa |
Procede de preparation de 2h-1-benzopyranes et intermediaires de synthese utiles dans la mise en oeuvre du procede
|
CN1280561A
(zh)
*
|
1997-10-02 |
2001-01-17 |
三共株式会社 |
酰胺基羧酸衍生物
|
EP0916665A1
(de)
*
|
1997-11-11 |
1999-05-19 |
Lonza A.G. |
Verfahren zur Herstellung von Chromanderivaten
|
KR100567183B1
(ko)
*
|
1997-11-14 |
2006-06-13 |
론자 아게 |
포르밀이미다졸의제조방법
|
HUP9902721A2
(hu)
*
|
1997-11-25 |
1999-12-28 |
The Procter & Gamble Co. |
Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
|
AU1507799A
(en)
*
|
1997-12-16 |
1999-07-05 |
Sankyo Company Limited |
Leukemia remedy
|
US20040058873A1
(en)
*
|
1998-03-12 |
2004-03-25 |
Esmond Robert W. |
Method for treating or preventing Alzheimer's disease
|
NZ506202A
(en)
|
1998-03-19 |
2003-10-31 |
Bristol Myers Squibb Co |
Biphasic controlled release delivery system for high solubility pharmaceuticals and method
|
WO2000007582A2
(en)
*
|
1998-08-06 |
2000-02-17 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
|
WO2000010994A1
(en)
*
|
1998-08-19 |
2000-03-02 |
Sankyo Company, Limited |
Process for the preparation of 2-(aryloxymethyl)-2,5,7,8-tetramethylchroman-6-ols
|
TR200100773T2
(tr)
|
1998-09-17 |
2001-07-23 |
Bristol-Myers Squibb Company |
Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı diyabet tedavi yöntemi
|
US6028088A
(en)
*
|
1998-10-30 |
2000-02-22 |
The University Of Mississippi |
Flavonoid derivatives
|
NZ511614A
(en)
|
1998-11-12 |
2003-12-19 |
Smithkline Beecham P |
Modified release pharmaceutical composition containing the insulin sensitiser 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and the antidiabetic agent metaformin
|
AR023699A1
(es)
*
|
1998-11-12 |
2002-09-04 |
Smithkline Beecham Corp |
Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
|
GB9824893D0
(en)
*
|
1998-11-12 |
1999-01-06 |
Smithkline Beckman Corp |
Novel method of treatment
|
AU1740900A
(en)
*
|
1998-11-20 |
2000-06-13 |
Genentech Inc. |
Method of inhibiting angiogenesis
|
US6191154B1
(en)
|
1998-11-27 |
2001-02-20 |
Case Western Reserve University |
Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
|
US5968960A
(en)
*
|
1999-01-14 |
1999-10-19 |
The Regents Of The University Of California |
Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism
|
US6204288B1
(en)
|
1999-03-08 |
2001-03-20 |
The University Of Mississippi |
1,2-dithiolane derivatives
|
US6127394A
(en)
*
|
1999-03-08 |
2000-10-03 |
The University Of Mississippi |
1,2-Dithiolane derivatives
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
US7041691B1
(en)
*
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
JP2001072592A
(ja)
|
1999-07-01 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
テロメラーゼ阻害剤
|
US6878749B2
(en)
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
CO5200844A1
(es)
|
1999-09-17 |
2002-09-27 |
Novartis Ag |
Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
KR100716525B1
(ko)
|
1999-12-03 |
2007-05-10 |
교토 야쿠힝 고교 가부시키가이샤 |
신규한 헤테로시클릭 화합물과 이의 염 및 이들의 의약 용도
|
DE60132723T2
(de)
|
2000-01-21 |
2009-01-29 |
Novartis Pharma Ag |
Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
US6784199B2
(en)
|
2000-09-21 |
2004-08-31 |
Aryx Therapeutics |
Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
|
US6680387B2
(en)
*
|
2000-04-24 |
2004-01-20 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6958355B2
(en)
*
|
2000-04-24 |
2005-10-25 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
WO2001082916A2
(en)
*
|
2000-05-03 |
2001-11-08 |
Tularik Inc. |
Combination therapeutic compositions and methods of use
|
GB0014969D0
(en)
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
US20030171399A1
(en)
*
|
2000-06-28 |
2003-09-11 |
Tularik Inc. |
Quinolinyl and benzothiazolyl modulators
|
NZ524519A
(en)
|
2000-08-07 |
2004-09-24 |
Ranbaxy Signature Llc |
Liquid formulation of metformin
|
FR2816840B1
(fr)
*
|
2000-11-17 |
2004-04-09 |
Flamel Tech Sa |
Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
|
US6452014B1
(en)
|
2000-12-22 |
2002-09-17 |
Geron Corporation |
Telomerase inhibitors and methods of their use
|
AU2002254567B2
(en)
|
2001-04-11 |
2007-10-11 |
Bristol-Myers Squibb Company |
Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
|
US20060047000A1
(en)
*
|
2001-04-24 |
2006-03-02 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
CA2448634A1
(en)
*
|
2001-05-29 |
2002-12-05 |
Kyoto Pharmaceutical Industries, Ltd. |
Novel heterocyclic compound and medicinal use thereof
|
US6872732B2
(en)
*
|
2001-05-29 |
2005-03-29 |
Kyoto Pharmaceutical Industries, Ltd. |
Heterocyclic derivatives and medicinal use thereof
|
JP4152641B2
(ja)
*
|
2001-08-07 |
2008-09-17 |
クラシエ製薬株式会社 |
チアゾリジン誘導体の副作用軽減剤
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
US8101209B2
(en)
*
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
WO2003043624A1
(en)
*
|
2001-11-16 |
2003-05-30 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US7015345B2
(en)
*
|
2002-02-21 |
2006-03-21 |
Asahi Kasei Pharma Corporation |
Propionic acid derivatives
|
KR20040088519A
(ko)
|
2002-02-22 |
2004-10-16 |
뉴 리버 파마슈티칼스, 인크. |
활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
|
WO2003084517A2
(fr)
*
|
2002-04-09 |
2003-10-16 |
Flamel Technologies |
Suspension orale de microcapsules d’amoxicilline
|
PT1492511E
(pt)
|
2002-04-09 |
2009-04-09 |
Flamel Tech Sa |
Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
|
WO2003096548A2
(de)
*
|
2002-05-14 |
2003-11-20 |
Siemens Aktiengesellschaft |
Verfahren zum erzeugen eines sendesignals
|
US8216609B2
(en)
*
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
US8268352B2
(en)
*
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
US20040176425A1
(en)
*
|
2003-01-24 |
2004-09-09 |
Washburn William N. |
Cycloalkyl containing anilide ligands for the thyroid receptor
|
EP2664672A1
(en)
*
|
2003-04-17 |
2013-11-20 |
Alnylam Pharmaceuticals Inc. |
Modified iRNA agents
|
US7851615B2
(en)
*
|
2003-04-17 |
2010-12-14 |
Alnylam Pharmaceuticals, Inc. |
Lipophilic conjugated iRNA agents
|
US8796436B2
(en)
|
2003-04-17 |
2014-08-05 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
US8017762B2
(en)
*
|
2003-04-17 |
2011-09-13 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
US7723509B2
(en)
|
2003-04-17 |
2010-05-25 |
Alnylam Pharmaceuticals |
IRNA agents with biocleavable tethers
|
US20050004179A1
(en)
*
|
2003-05-22 |
2005-01-06 |
Pedersen Ward A. |
Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7223761B2
(en)
*
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7674913B2
(en)
*
|
2003-11-12 |
2010-03-09 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
WO2006017292A1
(en)
*
|
2004-07-12 |
2006-02-16 |
Phenomix Corporation |
Constrained cyano compounds
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
BRPI0519006A2
(pt)
*
|
2004-12-13 |
2008-12-23 |
Daiichi Sankyo Co Ltd |
uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
|
US7317024B2
(en)
|
2005-01-13 |
2008-01-08 |
Bristol-Myers Squibb Co. |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
DE602006004964D1
(de)
*
|
2005-02-10 |
2009-03-12 |
Bristol Myers Squibb Co |
Dihydrochinazolinone als 5ht-modulatoren
|
US20070269486A1
(en)
*
|
2005-03-14 |
2007-11-22 |
Conor Medsystems, Llc. |
Methods and Devices for Reducing Tissue Damage After Ischemic Injury
|
KR20080025662A
(ko)
*
|
2005-03-18 |
2008-03-21 |
오키드 케미칼즈 앤드 파마수티컬즈 리미티드 |
신규 티로신 유도체
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7888381B2
(en)
|
2005-06-14 |
2011-02-15 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
|
AU2006275694A1
(en)
*
|
2005-07-28 |
2007-02-08 |
Bristol-Myers Squibb Company |
Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
US20080064884A1
(en)
*
|
2006-05-10 |
2008-03-13 |
Astrazeneca Ab |
Novel Process 1
|
WO2008057862A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
EP2089389A2
(en)
|
2006-11-01 |
2009-08-19 |
Bristol-Myers Squibb Company |
Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
|
CN101573340A
(zh)
|
2006-11-01 |
2009-11-04 |
百时美施贵宝公司 |
糖皮质激素受体AP-1和/或NF-κB活性的调节剂及其用途
|
KR101476472B1
(ko)
*
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
US20160331729A9
(en)
*
|
2007-04-11 |
2016-11-17 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US11241420B2
(en)
|
2007-04-11 |
2022-02-08 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
MX2009010854A
(es)
|
2007-04-11 |
2010-01-28 |
Omeros Corp |
Composiciones y metodos para profilaxis y tratamiento de adicciones.
|
CA3089569C
(en)
|
2007-06-04 |
2023-12-05 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
WO2009058944A2
(en)
|
2007-11-01 |
2009-05-07 |
Bristol-Myers Squibb Company |
Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
EP2321341B1
(en)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
CA2748034A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Pharmasset, Inc. |
Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
|
CN102325783A
(zh)
|
2008-12-23 |
2012-01-18 |
法莫赛特股份有限公司 |
嘌呤核苷的合成
|
PA8855601A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Forformidatos de nucleósidos
|
KR20170093264A
(ko)
|
2009-03-11 |
2017-08-14 |
오메로스 코포레이션 |
중독의 예방 및 치료용 조성물 및 방법
|
US10429384B2
(en)
|
2010-01-22 |
2019-10-01 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
|
SG184323A1
(en)
|
2010-03-31 |
2012-11-29 |
Gilead Pharmasett Llc |
Stereoselective synthesis of phosphorus containing actives
|
PL2590634T3
(pl)
|
2010-07-09 |
2016-10-31 |
|
Skojarzony system natychmiastowego / opóźnionego uwalniania leków o krótkim okresie półtrwania, w tym remogliflozyny
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US20120094959A1
(en)
|
2010-10-19 |
2012-04-19 |
Bonnie Blazer-Yost |
Treatment of cystic diseases
|
WO2014057522A1
(en)
|
2012-10-12 |
2014-04-17 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
CA2890086C
(en)
|
2012-11-05 |
2022-05-31 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) |
Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist preferably a thiazolid nedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
US10441560B2
(en)
|
2013-03-15 |
2019-10-15 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
CN105592846A
(zh)
|
2013-03-15 |
2016-05-18 |
持田制药株式会社 |
用于治疗非酒精性脂肪性肝炎的组合物和方法
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
CA2926685A1
(en)
|
2013-10-09 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
KR20240024362A
(ko)
|
2014-10-24 |
2024-02-23 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 fgf-21 폴리펩티드 및 그의 용도
|
WO2016071727A1
(en)
|
2014-11-04 |
2016-05-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
|
PE20210644A1
(es)
|
2018-07-19 |
2021-03-23 |
Astrazeneca Ab |
METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
|
US20220023252A1
(en)
|
2020-07-27 |
2022-01-27 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|